<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088906</url>
  </required_header>
  <id_info>
    <org_study_id>GECP09-01Phalcis</org_study_id>
    <secondary_id>2009-011327-31</secondary_id>
    <nct_id>NCT01088906</nct_id>
  </id_info>
  <brief_title>Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC</brief_title>
  <acronym>Phalcis</acronym>
  <official_title>Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with&#xD;
      advanced non-squamous cell lung cancer. This is a phase IIA pharmacogenomic trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, phase IIA pharmacogenomic, open label, uncontrolled, efficacy study&#xD;
      in patients with advanced non-squamous cell lung cancer as a first line therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No safety reasons. Low recruitment.&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Time to progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time until death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Carcinoma, Non Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>1 ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed/Cisplatin</intervention_name>
    <description>Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.</description>
    <arm_group_label>1 ARM</arm_group_label>
    <other_name>The Tradename of pemetrexed is Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of non-squamous NSCLC, that is not amenable to&#xD;
             curative treatment with surgery or radiation therapy. This population encompasses&#xD;
             advanced stage patients with select stage IIIB (with pleural or pericardial effusion)&#xD;
             or stage IV disease. Histologic or cytologic documentation of recurrence is required&#xD;
             in patients who were previously completely resected and now have progressive disease.&#xD;
&#xD;
          -  Tissue must be available to generate and apply the genomics predictor. If not obtained&#xD;
             at the time of diagnosis, then subject must consent to another biopsy. If patient had&#xD;
             prior radiation therapy, tissue biopsy for genomics analysis must be outside radiation&#xD;
             field.&#xD;
&#xD;
          -  At least one, non-radiated, measurable lesion by RECIST criteria.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  No prior chemotherapy, biologic or targeted therapy for any malignancy.&#xD;
&#xD;
          -  Prior radiation therapy is permitted if ≥1 week since completion of radiation&#xD;
             treatment. Radiation must be &lt;25% of bone marrow reserve.&#xD;
&#xD;
          -  Age greater than 18 years.&#xD;
&#xD;
          -  No previous or concomitant malignancy in the past 5 years other than surgical&#xD;
             management for carcinoma in situ of the cervix or basal cell or squamous cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
          -  No other serious medical or psychiatric illness.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Females of child-bearing potential (not surgically sterilized and between menarche and&#xD;
             1 year post menopause) must test negative for pregnancy within 7 days prior to or at&#xD;
             the time of enrollment based on a serum pregnancy test. Both sexually active males and&#xD;
             females of reproductive potential must agree to use a reliable method of birth&#xD;
             control, as determined by the patient and their health care team, during the study and&#xD;
             for 3 months following the last dose of study drug.&#xD;
&#xD;
          -  Required laboratory data within two weeks of enrollment:&#xD;
&#xD;
               1. ANC or AGC greater than 1500 per uL&#xD;
&#xD;
               2. Platelets greater than 100,000 per uL&#xD;
&#xD;
               3. Total bilirubin less than 1.5mg/dL&#xD;
&#xD;
               4. Creatinine clearance greater than or equal to 45 ml/min.&#xD;
&#xD;
               5. SGOT/SGPT less than or equal to 3x/ULN except in presence of known hepatic&#xD;
                  metastases in which it may be up to 5x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with squamous cell NSCLC.&#xD;
&#xD;
          -  Treatment within the last 30 days with a drug that has not received regulatory&#xD;
             approval for any indication at the time of study entry.&#xD;
&#xD;
          -  Concurrent administration of any other anti-tumor therapy.&#xD;
&#xD;
          -  Inability to comply with protocol or study procedures.&#xD;
&#xD;
          -  Active infection requiring IV antibiotics, antifungal or antiviral agents, that in the&#xD;
             opinion of the investigator would compromise the patient's ability to tolerate&#xD;
             therapy.&#xD;
&#xD;
          -  Documented symptomatic or untreated central nervous system (CNS) metastases (except if&#xD;
             adequately treated and stable for at least 2 weeks).&#xD;
&#xD;
          -  Major surgery within 2 weeks of study or other serious concomitant systemic disorders&#xD;
             that, in the opinion or the investigator, would compromise the safety of the patient&#xD;
             or compromise the patient's ability to complete the study.&#xD;
&#xD;
          -  Myocardial infarction having occurred less than 6 months before inclusion, any known&#xD;
             uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia or cardiac&#xD;
             failure not controlled by medications.&#xD;
&#xD;
          -  Have peripheral neuropathy of CTCAE Grade 1 or higher&#xD;
&#xD;
          -  Contraindications to corticosteroids.&#xD;
&#xD;
          -  Inability or unwillingness to take folic acid or vitamin B12 supplementation.&#xD;
&#xD;
          -  Unwillingness to stop taking herbal supplements while on study.&#xD;
&#xD;
          -  Presence of clinically significant third-space fluid collections (for example, ascites&#xD;
             or pleural effusions) that cannot be controlled by drainage or other procedures prior&#xD;
             to study entry and throughout study enrollment as the distribution of pemetrexed in&#xD;
             this fluid space is not fully understood.&#xD;
&#xD;
          -  Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.&#xD;
&#xD;
          -  Have prior known allergic/hypersensitivity reaction to any of the components of study&#xD;
             treatment&#xD;
&#xD;
          -  Inability to discontinue administration of aspirin at a dose greater than 1300 mg/day&#xD;
             or other non-steroidal anti-inflammatory agents for 2 days before, the day of, and 2&#xD;
             days after the dose of pemetrexed (5 days for long-acting agents such as piroxicam).&#xD;
&#xD;
          -  Female patients that is pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Miguel Sánchez Torres, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Lung Cancer Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Clínica Benidorm</name>
      <address>
        <city>Benidorm</city>
        <state>Alicante</state>
        <zip>03501</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>088916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Insular de Gran Canarias</name>
      <address>
        <city>Las Palmas de Gran Canarias</city>
        <state>Gran Canarias</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Spanish Lung Cancer Group website</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phalcis</keyword>
  <keyword>BRCA1</keyword>
  <keyword>RAP80</keyword>
  <keyword>TS</keyword>
  <keyword>First line</keyword>
  <keyword>Non-squamous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

